NanoSmart Welcomes Reg Wilson, Founder of EPIC Wealth, to Advisory Board

LAGUNA HILLS, Calif., Feb. 24, 2015 /PRNewswire/ -- NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing improved cancer therapies using a proprietary targeted nanoparticle platform technology, has appointed Mr. Reg Wilson to its advisory board. Mr. Wilson has extensive experience in advising companies in business development and strategic financial matters.

"NanoSmart's technology provides a rare opportunity to impact the lives of millions of cancer patients while also enabling high equitable growth potential for its shareholders," states Mr. Wilson. "I'm pleased to join NanoSmart's advisory board and to help NanoSmart bring its improved therapies to market."

Mr. Wilson is a registered investment advisor with over thirty years of experience in the financial industry providing wealth management strategies for both businesses and individuals. As founder and CEO of EPIC Wealth Advisors, Inc. and EPIC Financial, Mr. Wilson has a successful track record in guiding the financial growth of his clients and has developed an extensive network of financial and professional resources with experience in early stage growth companies.

"We are honored to have Reg join our advisory board," observed Dr. James Smith, President of NanoSmart. "In order to be successful, it is critical for biotechnology companies to have the support of a wide variety of talented and experienced individuals. Reg has already helped shape NanoSmart's business strategies, and his expertise in strategic growth will be an incredible asset as NanoSmart continues to emerge as a development-stage company."

About NanoSmart Pharmaceuticals

NanoSmart Pharmaceuticals, Inc. is a privately-held company engaged in developing novel methods to treat cancer and other diseases. The company is focused on using its patented tumor targeting antibodies to develop a variety of biopharmaceuticals to treat many different types of cancer. This press release may contain forward-looking statements that involve risks and uncertainties associated with product development and other business operations. NanoSmart's drug compounds are not approved by the FDA or other comparable regulatory agency. There can be no assurance that these forward-looking statements will prove to be accurate, and they should not be regarded as a representation that the objectives and plans will be achieved.

Contact
Dan Thiel, Investor Relations
(310) 951-3282; [email protected]

SOURCE NanoSmart Pharmaceuticals, Inc.

Related Links

http://www.nanosmartpharma.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED